Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07820566 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Development of a Preclinical 3D Vascularized and Perfused Tumoroid Model in Oncology and Urology Developed From Patient Tumors (Kidney, Bladder, and Prostate Cancers)

Name: Development of a Preclinical 3D Vascularized and Perfused Tumoroid Model in Oncology and Urology Developed From Patient Tumors (Kidney, Bladder, and Prostate Cancers) — clinical trial record (NCT07820566)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: 3DBlood

StatusRecruiting

PhaseNot specified

SponsorUniversity Hospital, Strasbourg, France

Started2024-09-02

View on ClinicalTrials.gov ↗

University Hospital, Strasbourg, France

315 trials monitored

See 7 trials at risk

Prostate Cancer

2,471 trials monitored

See 156 trials at risk

Bladder Cancer

1,018 trials monitored

See 64 trials at risk

Kidney Cancer

770 trials monitored

See 52 trials at risk

This is a study : * Single-center * Prospective * Translational * Based on data and blood samples. In this context, the aim is to collect approximately 10 ml of blood from each patient included in the 3D tumoroid development project. The main objective is to establish and validate a panel of vascularized and perfused 3D tumoroids for personalized medicine based on patient tumors for urological cancers, incorporating autologous immune cells. Translated with DeepL.com (free version)

Trial Details

NCT Number	NCT07820566
Lead Sponsor	University Hospital, Strasbourg, France
Conditions	Kidney Cancers, Bladder Cancer, Prostate Cancer
Enrollment	100 participants
Start Date	2024-09-02
Primary Completion	2029-09 (estimated)
Study Completion	2029-09 (estimated)
Updated on ClinicalTrials.gov	2026-09-15